The findings highlight JBQG's potential as a precision medicine candidate for RA patients with high lncRNA ITSN1-2 expression and provide a mechanistic framework for combining TCM with biologics (e.g., NOD2 inhibitors) to achieve synergistic effects. Here, ITSN1 is linked to rheumatoid arthritis.